CJC-1295 vs Ipamorelin
A comprehensive side-by-side comparison of CJC-1295 and Ipamorelin covering mechanisms, benefits, dosing, and safety.
Quick Verdict
CJC-1295 stimulates sustained growth hormone release via GHRH receptor activation, while Ipamorelin triggers pulsatile GH release through the ghrelin receptor. They are commonly stacked to mimic natural youthful GH patterns.
CJC-1295
CJC-1295 is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH), originally developed by ConjuChem Biotechnologies. It stimulates the pituitary gland to release growth hormone in a dose-dependent manner. It comes in two forms: with DAC (Drug Affinity Complex), which uses a maleimidopropionic acid linker to bind the peptide to serum albumin and extend its half-life to roughly 8 days, and without DAC (also called Mod GRF 1-29), which has a half-life of about 30 minutes and produces sharper, more natural GH pulses.
View Full ProfileIpamorelin
Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist. It is known for producing a clean growth hormone release without significantly affecting cortisol or prolactin levels, making it one of the safest GH-releasing peptides.
View Full ProfileAt a Glance
Mechanism of Action
CJC-1295
CJC-1295 binds to GHRH receptors (GHRH-R) on somatotroph cells in the anterior pituitary gland, triggering the production and pulsatile release of growth hormone. The DAC modification — a reactive chemical group that covalently attaches to circulating serum albumin after injection — prevents enzymatic degradation and renal clearance, extending the peptide's half-life from approximately 30 minutes to 8 days. Without DAC, the peptide is cleared rapidly, producing a GH spike that more closely mimics the body's natural pulsatile secretion pattern. Both forms increase IGF-1 levels downstream.
Ipamorelin
Ipamorelin selectively binds to ghrelin receptors in the pituitary gland, triggering the release of growth hormone. Unlike other GHRPs, it does not significantly increase appetite, cortisol, acetylcholine, prolactin, or aldosterone.
Potential Benefits
CJC-1295
- + Increased growth hormone levels
- + Improved body composition
- + Enhanced fat metabolism
- + Better sleep quality
- + Increased muscle mass
Ipamorelin
- + Clean GH release
- + Minimal side effects
- + Improved sleep
- + Enhanced recovery
- + Better body composition
Side Effects
CJC-1295
- ! Water retention
- ! Tingling or numbness
- ! Fatigue
- ! Flushing
Ipamorelin
- ! Headache (mild)
- ! Dizziness
- ! Flushing
- ! Injection site reactions
Research Areas
CJC-1295
Ipamorelin
Frequently Asked Questions
Should I use CJC-1295 or Ipamorelin?
Most researchers use both together. CJC-1295 provides a sustained baseline elevation of growth hormone, while Ipamorelin adds natural pulsatile release patterns. Together, they more closely mimic youthful GH secretion than either alone.
What is the difference between CJC-1295 and Ipamorelin?
CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that acts on the GHRH receptor for sustained GH release. Ipamorelin is a growth hormone secretagogue that acts on the ghrelin receptor for pulsatile GH release. They work through different mechanisms.
Related Comparisons
Explore These Peptides
Learn more about each peptide or find optimized stacking protocols.